PERAMPANEL AS MONOTHERAPY IN OPEN-LABEL EXTENSION STUDIES

Abstract

Perampanel, a selective, non-competitive AMPA receptor antagonist, is approved for adjunctive treatment of focal seizures, with or without secondary generalised seizures, and for primary generalised tonic-clonic seizures in patients with epilepsy aged ≥12 years. We analysed the seizure outcomes of individuals with focal seizures who discontinued all non-perampanel antiepileptic drugs (AEDs) and continued to receive perampanel (up to 12 mg/day) as monotherapy in two open-label extension (OLEx) studies: Study 307 (NCT00735397) and the Study 235 OLEx (NCT01161524). Seven patients discontinued all concomitant AEDs and took perampanel as monotherapy (Study 307, n=6; Study 235 OLE, n=1; female, n=..